2023-10-17 06:22:23
The Danish laboratory Novo Nordisk, specialist in anti-diabetic and anti-obesity treatments, announced Monday the acquisition of ocedurenone, a drug once morest hypertension, for a sum of up to 1.3 billion dollars (1.23 billion euros).
The molecule, developed by the biotech KBP Biosciences, is currently the subject of clinical trials in patients suffering from uncontrolled hypertension and chronic renal failure.
Uncontrolled hypertension is among the main risk factors for cardiovascular disease, chronic kidney failure and premature death, noted Novo Nordisk in a press release.
“With the expected benefit-risk profile, ocedurenone has best-in-class potential for the treatment of uncontrolled hypertension and might help address a major unmet medical need,” said Martin Holst Lange, head of the development at Novo Nordisk, cited in the press release.
The acquisition, which must be finalized before the end of the year, will not affect the results of the Nordic flagship.
On Friday, the laboratory, the largest European market capitalization, raised its forecasts for 2023 thanks to sales of its anti-diabetic and anti-obesity treatments, Ozempic and Wegovy.
Its turnover, which had reached 176.95 billion crowns (23.7 billion euros) in 2022, is expected to increase from 32% to 38% in 2023, or five points more than what it had announced previously.
Access to all features is reserved for healthcare professionals.
If you are a healthcare professional you must log in or register for free on our site to access all of our content.
If you are a journalist or if you wish to inform us, write to us at [email protected].
1697526925
#Novo #Nordisk #acquires #blood #pressure #drug #billion
